EHA 2019 | First-line treatment of SAA: towards a new standard of care?

Regis Peffault de Latour

Regis Peffault de Latour, MD, PhD, Saint Louis Hospital, Paris, France, discusses novel combination therapies for the treatment of severe aplastic anemia (SAA). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics
Related videos
1:01
Aplastic anemia: EHA highlights
Regis Peffault de Latour
1:36
Sotatercept for MPN-associated myelofibrosis and anemia
Srdan Verstovsek
1:53
Telomere length screening
Carlo Dufour
3:36
New insights in Fanconi anemia
Carlo Dufour
1:29
Treating Patients with PNH and AA
Anita Hill
Anemia, Aplastic Anemia
Cyclosporin, Eltrombopag, hTG
Race
EHA 2019
Interview
15th June 2019
More from Regis Peffault de Latour
Transplantation for PNH?
Challenges in the management of idiopathic aplastic anemia
Aplastic anemia: EHA highlights
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals